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Abstract
Background: Currently, there are no standard guidelines for recommending re-administration of a
chemotherapeutic drug to a patient after a serious adverse drug reaction (ADR) incident. The decision on whether
to rechallenge the patient is based on the experience of the clinician and is highly subjective. Thus the aim of this
study is to develop a decision support tool to assist clinicians in this decision making process.
Methods: The inclusion criteria for patients in this study are: (1) had chemotherapy at National Cancer Centre
Singapore between 2004 to 2009, (2) suffered from serious ADRs, and (3) were rechallenged. A total of 46 patients
fulfilled the inclusion criteria. A genetic algorithm attribute selection method was used to identify clinical predictors
for patients’ rechallenge status. A Naïve Bayes model was then developed using 35 patients and externally
validated using 11 patients.
Results: Eight patient attributes (age, chemotherapeutic drug, albumin level, red blood cell level, platelet level,
abnormal white blood cell level, abnormal alkaline phosphatase level and abnormal alanine aminotransferase level)
were identified as clinical predictors for rechallenge status of patients. The Naïve Bayes model had an AUC of 0.767
and was found to be useful for assisting clinical decision making after clinicians had identified a group of patients
for rechallenge. A platform independent version and an online version of the model is available to facilitate
independent validation of the model.
Conclusion: Due to the limited size of the validation set, a more extensive validation of the model is necessary
before it can be adopted for routine clinical use. Once validated, the model can be used to assist clinicians in
deciding whether to rechallenge patients by determining if their initial assessment of rechallenge status of patients
is accurate.
Background
The chemotherapeutic drug class was identified as the
most common class for adverse drug reactions (ADR),
accounting for 21.8% of 408 ADRs reported in an Indian
hospital [1]. Patients on chemotherapy may experience
serious ADRs which can be potentially fatal and may
require costly interventions. 10.5% of 4075 women on
chemotherapy had hospitalizations or emergency room
visits for serious ADRs, resulting in an additional $1271
per person annually [2]. However, re-introduction of
chemotherapeutic agents may be required due to the
lack of alternative treatments. Currently, there are no
standard guidelines for recommending re-administration
of the chemotherapeutic drug to the patient after a ser-
ious ADR incident. Thus, management decisions are
based purely on the experience of the clinicians and are
highly subjective. Although patients with mild ADRs can
usually be re-administered with the drug without much
risks, there is still no consensus on whether patients
with serious ADRs should be re-administered with the
drug. This is because there are currently no methods
* Correspondence: phayapc@nus.edu.sg
1Department of Pharmacy, National University of Singapore, Singapore
Full list of author information is available at the end of the article
Loke et al. BMC Cancer 2011, 11:319
http://www.biomedcentral.com/1471-2407/11/319
© 2011 Loke et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.which can accurately identify patients who will have
negative rechallenge (ADRs do not re-occur upon re-
administration of drug) or positive rechallenge (ADRs
re-occur upon re-administration of drug). Thus, it will
be useful to have a method that can predict patients’
rechallenge status in order to improve patient safety and
assist in chemotherapy choices.
Data mining is the use of sophisticated data analysis
tools to discover patterns and relationships in large data
set [3]. It can build computational models from data sets
by learning from past experiences. Applications of data
mining have been widely used in many diverse areas like
business, medical research and pharmacovigilance. For
example, Nordyke et al. proposes the use of Naïve Bayes
in the automated diagnosis of thyroid dysfunction [4].
Hence, data mining methods could potentially be useful
in analyzing an ADRs database and identifying important
clinical predictors for patients’ rechallenge status.
The aim of this study is to develop a clinical decision
support tool, using data mining methods, to assist in
determining the appropriateness of re-introducing a
chemotherapeutic agent following the confirmatory
association between the drug and the occurrence of a
serious ADR in a patient. A Naïve Bayes method was
used to analyze differences between the profiles of
patients with negative rechallenge and those with posi-
tive rechallenge, and to develop a model to predict the
patients’ rechallenge status. Naïve Bayes was selected as
it has been shown to produce relatively good classifica-
tion performance and is straightforward in implementa-
tion [5]. A genetic algorithm (GA) attribute selection
method was used to identify clinical predictors that
could differentiate patients with negative challenge from
those with positive rechallenge. GA can identify several
combinations of clinical predictors that are equally
good. This allows analysis of the results and selection of
the most clinically relevant attributes as predictors.
Methods
Data collection
A total of 854 patients who were treated at the National
Cancer Centre Singapore (NCCS) during the period 2004-
2009 and experienced ADRs from chemotherapeutic
agents were identified using spontaneous ADR reporting
forms. Among these patients, 81 experienced serious ADR
and 46 of them were rechallenged. These include 23 nega-
tive rechallenge cases and 23 positive rechallenge cases.
Information about these 46 patients’ demographics, rele-
vant medical records and laboratory values were collected
from the case notes and electronic medical systems.
Preprocessing
The dataset was split into 3 sets: training, testing and
validation. A total of 24 cases were randomly selected
from the 35 cases that occurred between 2004 to 2008
to form the training set for developing the Naïve Bayes
model. All the 35 cases were used as the testing set to
test the performance of the model during the GA attri-
bute selection process. The 11 cases that occurred dur-
ing 2009 were used as an independent validation set to
validate the model. These 11 cases were not used during
the development of the model or during attribute
selection.
Patient’s attributes
Patient’s attributes that may have potential associations
with rechallenge status and which were readily available
were collected for the 46 patients. The attributes, given
in Table 1, can be broadly categorized into the following
groups: (1) patient demographics, (2) medical condi-
tions, (3) medications usage, (4) laboratory parameters.
Genetic variables were not included in the study as
genetic testing is not commonly conducted in NCCS.
Discrete categories of attributes were derived from
some of the continuous attributes. For example, age was
Table 1 Patient’s attributes that were collected in this study
Attributes
Demographics - Age - Gender - Ethnicity
- Weight
Medical Conditions - Drug allergy - Cancer type - Cancer malignancy
- Comorbidities - Symptoms of the ADRs - Hospitalization for prior
- ADRs affected organ systems - Onset of ADRs ADRs
Medications - Number of cycles - Chemotherapeutic drug - Chemotherapeutic drug class
- Number of doses - Concurrent medications
- Dose reduction on rechallenge - Rechallenge on same day
Laboratory parameters - White blood cell - Red blood cell - Eosinophil
- Neutrophil - Platelet - Monocyte
- Lymphocyte - Serum creatinine - Alkaline Phosphatase
- Alanine aminotransferase - Aspartate aminotransferase - Basophil
- Albumin
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able with 2 categories: elderly (65 years old and above)
and non-elderly (less than 65 years old) [6]. The number
of concurrent medications was also categorized into a
binomial attribute to test for possible associations
between polypharmacy and rechallenge status. The defi-
nition of “more than 5 concomitant drugs” for serious
polypharmacy [7] was adopted in this study. In addition
to the presence of comorbidities, the number of comor-
bidities for each patient was also calculated. These
comorbidities include hypertension, diabetes, hyperlipi-
demia, psoriasis, gastroestrophageal reflux disease
(GERD), asthma and other allergic disorders. Other
additional attributes constructed include the class of
chemotherapeutic agents, types and malignancy of can-
cer, and types of ADRs experienced.
Laboratory parameters used include full blood count
(white blood cell, red blood cell, platelet, neutrophil,
lymphocyte, monocyte, eosinophil and basophil levels),
renal indices (serum creatinine) and liver indices (aspar-
tate aminotransferase, alanine aminotransferase and
alkaline phosphatase). These are routinely analyzed for
all patients in NCCS and the laboratory panels were
obtained from the most recent measurements before the
reported ADR incident. Additional attributes represent-
ing the presence or absence of abnormal laboratory
parameters were also constructed.
The total number of attributes used for data mining
was 53. Detailed information on these 53 attributes is
provided in Additional File 1: Appendices 1 to 3.
Genetic Algorithm Attribute Selection
GA was used to rank and select attributes that are use-
ful for predicting patients’ rechallenge status. Figure 1
shows an overview of the GA attribute selection process.
The process involved creating multiple ‘generations’ of
attribute subsets. Each attribute subset contained
between 1 to 53 attributes that were initially randomly
chosen. During each ‘generation’, a Naïve Bayes model
was developed using the training set for each of the 80
attribute subsets in the population. A fitness value was
determined for each model by using the testing set to
compute the area under the receiver operating charac-
teristic curve (AUC). The roulette wheel method was
used as the selection operator for reproduction and
population replacement. Crossover and mutation rates
of 95% and 5% were used respectively to construct new
attribute subsets for the next ‘generation’.T h i sp r o c e s s
was repeated until 100 ‘generations’ was reached. The
GA attribute selection process was repeated 5 times
using different starting ‘generation’ of attribute subsets.
T h eb e s ta t t r i b u t es u b s e tw i t ht h eh i g h e s tA U Cf r o m
these 5 runs was chosen. The clinical predictors were
then selected from this attribute subset by expert assess-
ment of the Naïve Bayes distribution table and clinical
significance of the predictors. The final Naïve Bayes
model was then developed using the 35 cases that
occurred between 2004-2008 and the selected clinical
predictors.
Naïve Bayes
Naïve Bayes is a simple probabilistic classification algo-
rithm based on Bayes’ theorem and has the assumption
of conditional independence of the predictive attributes
[8,9]. Given a set of patient attributes, F = {F1,F 2... Fn},
the posterior probability of a patient having negative
rechallenge (NR) under the assumption of independence
of the attributes can be computed as follows:
P(NR|F)=
P(F1|NR)P(NR)...P(Fn|NR)P(NR)
[[P(NR)P(F1|NR)]... + ...[P(NR)P(Fn|NR)]]
Performance Evaluation
The performance of the model was measured using
AUC, which is frequently used to evaluate prediction
models in the biomedical informatics field [10,11]. In
addition, the sensitivity and specificity of the model
were calculated. Sensitivity refers to the proportion of
patients with negative rechallenge who are predicted to
1
Starting population= 80
Initialize with N randomly 
selected attributes
Training set Naïve Bayes
Testing set
Determine 
fitness of each 
attribute subset
Crossover
Mutation
Selection
Form new 
population
Termination when fitness 
cannot be improved
Select most optimal 
attribute subset
Figure 1 Overview of the Genetic Algorithm attribute selection process.
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portion of patients with positive rechallenge who are
predicted to have positive rechallenge.
Results
Clinical Predictors
The set of clinical predictors identified by GA and
refined by expert assessment is listed in Table 2.
Patients’ rechallenge status was found to be associated
with age. The mean age for positive rechallenge cases
were higher (55.55 ± 14.18) compared to negative
rechallenge cases (47.71 ± 14.87). The type of che-
motherapeutic agents administered was also found to be
a significant clinical predictor, with patients who were
given carboplatin, paclitaxel, docetaxel and cetuximab
being more likely to have positive rechallenge. The
mean albumin level for patients with positive rechal-
lenge was 30.9 g/l, compared to 35.7 g/l for patients
with negative rechallenge. Mean platelet and red blood
cell (RBC) levels were found to be lower in patients who
have positive rechallenge. Patients with abnormal levels
of alanine aminotransferase (ALT), alkaline phosphatase
(AP) and white blood cell (WBC) were more likely to
have positive rechallenge.
Naïve Bayes model
The Naïve Bayes model developed using the 35 cases
that occurred between 2004-2008 and the selected
clinical predictors had an AUC of 0.767 for the valida-
tion set.
A platform independent version and an online version
of the model (PaDEL-Rechallenge) is available at http://
padel.nus.edu.sg/software/padelrechallenge. This will
facilitate independent validation of the model by
clinicians.
Discussion
Clinical predictors
It is important to note that the identified clinical predic-
tors in this study were only found to be associated with
rechallenge status. However, association does not imply
causality. It is also essential to note that most of these
were weak associations, but when considered together in
the Naïve Bayes model, they were found to be useful for
predicting patients’ rechallenge status. Detailed discus-
sion on the individual predictors can be found in Addi-
tional File 1: Appendix 4.
Performance
Since there are no similar studies that develop models
for predicting patients’ rechallenge status, we will assess
the performance of our model by making tentative com-
parisons with other models developed in other biomedi-
cal fields. A Naïve Bayes and Radial Basis Function
method for predicting implantation potentials of IVF
embryos reported superior performance with an AUC of
Table 2 Descriptive statistics of clinical predictors in testing set (n = 35)
Numerical attributes Negative rechallenge (Mean +/- SD) Positive rechallenge (Mean +/- SD)
Age 47.7 +/- 14.9 55.4 +/- 14.2
Albumin level 35.7 +/- 4.6 30.9 +/- 5.6
RBC level 4.06 +/- 0.58 3.69 +/- 0.81
Platelet level 331.41 +/- 153.62 324.39 +/- 150.86
Categorical and binominal attributes Negative rechallenge (proportion) Positive rechallenge (proportion)
Chemotherapeutic drug
Oxaliplatin 0.294 0.278
Carboplatin 0.059 0.278
Bleomycin 0.059 0.000
Rituximab 0.235 0.000
Paclitaxel 0.118 0.167
Docetaxel 0.059 0.111
Trastuzumab 0.118 0.056
Cetuximab 0.000 0.056
Gemcitabine 0.059 0.056
Laboratory parameters
Abnormal WBC level* 0.118 0.444
Abnormal ALT level* 0.118 0.278
Abnormal AP level* 0.176 0.556
*Presence of abnormal level is allocated value of 1 while absence of abnormal level is allocated value of 0.
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network model to differentiate between patients with
and without prostate cancer had an AUC range of 0.77
to 0.81 [13]. Thus, our Naïve Bayes model with an AUC
of 0.767 can be considered to have acceptable prediction
performance.
It is important to note that the rechallenge status of
those patients who were not rechallenged will never be
known. Since our model was not trained using this
group of patients, it is not justifiable to replace clinical
judgement with our model for predicting the rechallenge
status for all patients. Instead, a more suitable applica-
tion for our model will be to assist in subsequent clini-
cal decision making after clinicians had identified a
group of patients who are likely to have negative
rechallenge.
The 13 serious ADR cases that occurred in 2009 will
be used to illustrate the potential usefulness of our
model for this type of application. Initial clinical judge-
ment identified 11 cases as potentially negative rechal-
lenge cases. Out of these, 6 were negative rechallenge
cases and 5 were positive rechallenge cases. Thus initial
clinical judgement had a sensitivity of 100% and specifi-
city of 0%. Our Naïve Bayes model can be used to
improve the prediction accuracy of the clinicians by pro-
viding a score for each case. A threshold for the score
can be set and patients with scores above or below this
threshold will be predicted by the model as potential
negative or positive rechallenge cases respectively. Clini-
cians can choose different thresholds for the score
according to their treatment objectives for the patients.
For example, a low threshold is more important for
patients who are undergoing curative treatment so that
they are not deprived of a useful drug treatment. This is
a significant issue in chemotherapeutic treatment
because there are limited choices of effective chemother-
apeutic drugs available to the patients. Thus, the bene-
fits from using the first line drugs usually outweigh the
potential risks caused by any serious ADRs. The sensi-
tivity and specificity of our model using 0.01 as the
threshold is 100% and 20% respectively. Conversely, a
high threshold would be more useful for patients under-
going palliative chemotherapeutic treatment as the key
priority is to prevent them from experiencing unneces-
sary serious ADRs caused by rechallenge. A threshold of
0.8 would result in a sensitivity of 67% and specificity of
80% for our model.
Limitations
Despite analyzing 6 years worth of data, the size of the
dataset used to develop and validate our model is rather
small. This is due to the limited number of ADR cases
reported and collected in NCCS. Thus, this study is only
a pilot study and there is a need for further validation of
the accuracy and reproducibility of this model. A study
is currently ongoing to validate the model using 2010 to
2014 data. In addition, a visual aid will be added to
improve the interpretability of the results by clinicians.
Additional discussion on other limitations of this study
can be found in Additional File 1: Appendix 4.
Conclusion
Compared to clinical judgement, the Naïve Bayes model
developed in this study is able to guide rechallenge deci-
sions more consistently and thus allows clinicians to
make more confident decisions on whether to rechal-
lenge a patient with the same drug after a prior serious
ADR. The proposed use of the model is to assist in sub-
sequent clinical decision making after the clinicians had
identified a group of patients for rechallenge. Thus the
model serves as a subsequent check to reinforce or dis-
courage the initial decision for rechallenge. This would
help to reduce serious ADRs and improve patient’s
treatment options.
Additional material
Additional file 1: Appendices. Contains Appendix 1: Detailed list of
patient’s attributes collected or derived in this study Appendix 2.
Descriptive statistics for numerical attributes in testing and validation set
Appendix 3. Descriptive statistics for nominal attributes in testing and
validation set Appendix 4. Additional discussion
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